Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
Graves’ disease
Graves’ orbitopathy
Gut microbiota
Human fecal microbiota transplant
Microbiome modulation
Murine model
Probiotics
Vancomycin
Journal
Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147
Informations de publication
Date de publication:
16 02 2021
16 02 2021
Historique:
received:
05
11
2020
accepted:
06
12
2020
entrez:
17
2
2021
pubmed:
18
2
2021
medline:
19
3
2021
Statut:
epublish
Résumé
Graves' disease (GD) is an autoimmune condition in which autoantibodies to the thyrotropin receptor (TSHR) cause hyperthyroidism. About 50% of GD patients also have Graves' orbitopathy (GO), an intractable disease in which expansion of the orbital contents causes diplopia, proptosis and even blindness. Murine models of GD/GO, developed in different centres, demonstrated significant variation in gut microbiota composition which correlated with TSHR-induced disease heterogeneity. To investigate whether correlation indicates causation, we modified the gut microbiota to determine whether it has a role in thyroid autoimmunity. Female BALB/c mice were treated with either vancomycin, probiotic bacteria, human fecal material transfer (hFMT) from patients with severe GO or ddH2O from birth to immunization with TSHR-A subunit or beta-galactosidase (βgal; age ~ 6 weeks). Incidence and severity of GD (TSHR autoantibodies, thyroid histology, thyroxine level) and GO (orbital fat and muscle histology), lymphocyte phenotype, cytokine profile and gut microbiota were analysed at sacrifice (~ 22 weeks). In ddH2O-TSHR mice, 84% had pathological autoantibodies, 67% elevated thyroxine, 77% hyperplastic thyroids and 70% orbital pathology. Firmicutes were increased, and Bacteroidetes reduced relative to ddH2O-βgal; CCL5 was increased. The random forest algorithm at the genus level predicted vancomycin treatment with 100% accuracy but 74% and 70% for hFMT and probiotic, respectively. Vancomycin significantly reduced gut microbiota richness and diversity compared with all other groups; the incidence and severity of both GD and GO also decreased; reduced orbital pathology correlated positively with Akkermansia spp. whilst IL-4 levels increased. Mice receiving hFMT initially inherited their GO donors' microbiota, and the severity of induced GD increased, as did the orbital brown adipose tissue volume in TSHR mice. Furthermore, genus Bacteroides, which is reduced in GD patients, was significantly increased by vancomycin but reduced in hFMT-treated mice. Probiotic treatment significantly increased CD25 These results strongly support a role for the gut microbiota in TSHR-induced disease. Whilst changes to the gut microbiota have a profound effect on quantifiable GD endocrine and immune factors, the impact on GO cellular changes is more nuanced. The findings have translational potential for novel, improved treatments. Video abstract.
Sections du résumé
BACKGROUND
Graves' disease (GD) is an autoimmune condition in which autoantibodies to the thyrotropin receptor (TSHR) cause hyperthyroidism. About 50% of GD patients also have Graves' orbitopathy (GO), an intractable disease in which expansion of the orbital contents causes diplopia, proptosis and even blindness. Murine models of GD/GO, developed in different centres, demonstrated significant variation in gut microbiota composition which correlated with TSHR-induced disease heterogeneity. To investigate whether correlation indicates causation, we modified the gut microbiota to determine whether it has a role in thyroid autoimmunity. Female BALB/c mice were treated with either vancomycin, probiotic bacteria, human fecal material transfer (hFMT) from patients with severe GO or ddH2O from birth to immunization with TSHR-A subunit or beta-galactosidase (βgal; age ~ 6 weeks). Incidence and severity of GD (TSHR autoantibodies, thyroid histology, thyroxine level) and GO (orbital fat and muscle histology), lymphocyte phenotype, cytokine profile and gut microbiota were analysed at sacrifice (~ 22 weeks).
RESULTS
In ddH2O-TSHR mice, 84% had pathological autoantibodies, 67% elevated thyroxine, 77% hyperplastic thyroids and 70% orbital pathology. Firmicutes were increased, and Bacteroidetes reduced relative to ddH2O-βgal; CCL5 was increased. The random forest algorithm at the genus level predicted vancomycin treatment with 100% accuracy but 74% and 70% for hFMT and probiotic, respectively. Vancomycin significantly reduced gut microbiota richness and diversity compared with all other groups; the incidence and severity of both GD and GO also decreased; reduced orbital pathology correlated positively with Akkermansia spp. whilst IL-4 levels increased. Mice receiving hFMT initially inherited their GO donors' microbiota, and the severity of induced GD increased, as did the orbital brown adipose tissue volume in TSHR mice. Furthermore, genus Bacteroides, which is reduced in GD patients, was significantly increased by vancomycin but reduced in hFMT-treated mice. Probiotic treatment significantly increased CD25
CONCLUSIONS
These results strongly support a role for the gut microbiota in TSHR-induced disease. Whilst changes to the gut microbiota have a profound effect on quantifiable GD endocrine and immune factors, the impact on GO cellular changes is more nuanced. The findings have translational potential for novel, improved treatments. Video abstract.
Identifiants
pubmed: 33593429
doi: 10.1186/s40168-020-00952-4
pii: 10.1186/s40168-020-00952-4
pmc: PMC7888139
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Références
Endocrinology. 2016 Apr;157(4):1673-82
pubmed: 26872090
Thyroid. 2019 Sep;29(9):1286-1301
pubmed: 31237525
Endocrinology. 2013 Sep;154(9):3008-15
pubmed: 23900776
Nature. 2013 Dec 19;504(7480):451-5
pubmed: 24226773
Lancet Diabetes Endocrinol. 2017 Feb;5(2):134-142
pubmed: 27346786
Nat Methods. 2013 Dec;10(12):1200-2
pubmed: 24076764
J Endocrinol Invest. 2008 Jun;31(6):505-8
pubmed: 18591881
Curr Microbiol. 2014 Nov;69(5):675-80
pubmed: 24969306
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Sci Rep. 2017 Oct 20;7(1):13675
pubmed: 29057975
Nat Rev Endocrinol. 2010 Jun;6(6):311-8
pubmed: 20421883
Front Microbiol. 2011 Aug 01;2:166
pubmed: 21904534
Sci Rep. 2018 May 1;8(1):6854
pubmed: 29717179
Br J Ophthalmol. 2009 Aug;93(8):1052-6
pubmed: 19221109
Sci Rep. 2018 Aug 30;8(1):13096
pubmed: 30166557
Horm Metab Res. 2013 Aug;45(8):549-55
pubmed: 23613015
Sci Rep. 2015 Nov 06;5:16148
pubmed: 26541096
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10719-10724
pubmed: 28893994
Front Microbiol. 2019 Jul 17;10:1655
pubmed: 31379797
Cell Host Microbe. 2008 Oct 16;4(4):337-49
pubmed: 18854238
Eur Thyroid J. 2018 Jun;7(3):111-119
pubmed: 30023342
Ann Nutr Metab. 2012;61(2):160-74
pubmed: 23037511
Nat Microbiol. 2016 Aug 22;1(11):16140
pubmed: 27782139
J Clin Endocrinol Metab. 2020 Nov 1;105(11):
pubmed: 32785703
mBio. 2016 Dec 20;7(6):
pubmed: 27999162
J Endocrinol Invest. 2017 Jun;40(6):567-576
pubmed: 28063079
Am J Gastroenterol. 2017 Jun;112(6):948-950
pubmed: 28572645
Int J Biol Sci. 2018 Sep 7;14(11):1558-1570
pubmed: 30263008
PLoS One. 2010 Feb 02;5(2):e9009
pubmed: 20126401
Endocrinology. 2010 Apr;151(4):1940-7
pubmed: 20181794
Clin Immunol. 2017 Oct;183:63-74
pubmed: 28689782
J Clin Endocrinol Metab. 2003 May;88(5):1939-46
pubmed: 12727937
Cell. 2018 Sep 6;174(6):1388-1405.e21
pubmed: 30193112
Endocrinology. 2009 Feb;150(2):1051-60
pubmed: 18927213
Invest Ophthalmol Vis Sci. 2016 Nov 01;57(14):6123-6133
pubmed: 27832278
J Clin Endocrinol Metab. 2017 Nov 1;102(11):4273-4283
pubmed: 28938397
Cell Mol Gastroenterol Hepatol. 2016 Mar 03;2(4):468-481
pubmed: 27795980
Immunity. 2014 Sep 18;41(3):478-492
pubmed: 25220212
Horm Metab Res. 2013 Jun;45(6):401-7
pubmed: 23386414
J Endocrinol Invest. 2015 Mar;38(3):283-94
pubmed: 25421156
Front Cell Infect Microbiol. 2019 Apr 24;9:99
pubmed: 31069173
Sci Rep. 2016 Jun 27;6:28484
pubmed: 27346372
Nature. 2018 Oct;562(7728):589-594
pubmed: 30356183
ILAR J. 2015;56(2):205-17
pubmed: 26323630
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Br J Ophthalmol. 2003 Jun;87(6):773-6
pubmed: 12770979
PLoS One. 2011;6(11):e27644
pubmed: 22110705
Diabetologia. 2012 Aug;55(8):2285-94
pubmed: 22572803
Open Forum Infect Dis. 2016 May 05;3(2):ofw091
pubmed: 27822485
Nature. 2009 Oct 29;461(7268):1282-6
pubmed: 19865172
Neuroimmunomodulation. 2006;13(5-6):309-17
pubmed: 17709953
Int J Food Microbiol. 2005 Aug 15;103(1):97-104
pubmed: 16084270
Nat Rev Endocrinol. 2020 Feb;16(2):104-116
pubmed: 31889140
Microbiome. 2018 May 25;6(1):97
pubmed: 29801507
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
Microbiome. 2019 Jul 17;7(1):107
pubmed: 31315667
Nat Methods. 2011 Jul 17;8(9):761-3
pubmed: 21765408
Diabetologia. 2005 Aug;48(8):1565-75
pubmed: 15986236
Orphanet J Rare Dis. 2017 Apr 20;12(1):72
pubmed: 28427469
Clin Immunol Immunopathol. 1988 Nov;49(2):292-8
pubmed: 3262472
Saudi Med J. 2000 Jul;21(7):639-44
pubmed: 11500727
Nat Med. 2015 Aug;21(8):895-905
pubmed: 26214836
J Exp Med. 2017 Jan;214(1):107-123
pubmed: 27994068
Biol Sex Differ. 2016 Aug 24;7(1):36
pubmed: 27559466
Sci Rep. 2019 Sep 9;9(1):12918
pubmed: 31501492
Horm Metab Res. 2018 Dec;50(12):932-941
pubmed: 30107619
PLoS One. 2015 May 13;10(5):e0125448
pubmed: 25970503
Oncotarget. 2016 Mar 15;7(11):11803-16
pubmed: 26933816
J Endocrinol Invest. 2019 Aug;42(8):967-978
pubmed: 30674011
Gut Microbes. 2013 Mar-Apr;4(2):125-35
pubmed: 23333862
Appl Environ Microbiol. 2008 Mar;74(5):1646-8
pubmed: 18083887